Literature DB >> 25561208

The many clinico-pathologic faces of actinic keratosis: an atlas.

Cesare Massone1, Lorenzo Cerroni.   

Abstract

Actinic keratoses (AKs) are intraepithelial neoplasms formed by atypical keratinocyte proliferation. Histopathologically, typical AKs are characterized by a slightly thickened epidermis, usually with irregular downward buds, orthokeratosis alternating with parakeratosis ('pink and blue') with loss of the underlying granular layer and a disarrangement of the epidermis with atypical keratinocytes at the basal layer. There are several histopathological variants of AK according to the different degrees of keratinocytic atypia, epidermal hyperplasia/atrophy, inflammation and pigmentation. Some authors consider AK an early in situ squamous cell carcinoma and propose a classification of AK based on the extent of atypical keratinocytes in the epidermis.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25561208     DOI: 10.1159/000366538

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  4 in total

1.  Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages.

Authors:  Maria Antsiferova; Aleksandra Piwko-Czuchra; Michael Cangkrama; Mateusz Wietecha; Dilara Sahin; Katharina Birkner; Valerie C Amann; Mitchell Levesque; Daniel Hohl; Reinhard Dummer; Sabine Werner
Journal:  EMBO Mol Med       Date:  2017-01       Impact factor: 12.137

2.  Astragalin Attenuates UVB Radiation-induced Actinic Keratosis Formation.

Authors:  Na Li; Kun Zhang; Xin Mu; Qiong Tian; Wenli Liu; Tianyuan Gao; Xiaona Ma; Jian Zhang
Journal:  Anticancer Agents Med Chem       Date:  2018       Impact factor: 2.505

3.  Aligned nodules on the forearms.

Authors:  Fernanda Teixeira; Maria de Lourdes Bialon Santana; Maria L Cintra
Journal:  JAAD Case Rep       Date:  2021-01-05

4.  Protective effects of sunscreen (50+) and octatrienoic acid 0.1% in actinic keratosis and UV damages.

Authors:  Daniela Pinto; Anna Trink; Giammaria Giuliani; Fabio Rinaldi
Journal:  J Investig Med       Date:  2021-09-16       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.